Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials

Publisher： Bentham Science Publishers

E-ISSN： 1996-3181|12|8|1128-1142

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.12, Iss.8, 2013-12, pp. : 1128-1142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glutamate Receptors and Parkinson’s Disease: Opportunities for Intervention

By Marino M.J.   Valenti O.   Conn P.J.  

Drugs & Aging, Vol. 20, Iss. 5, 2003-01 ,pp. : 377-397

Adis International

Access to resources Recommend Favorite

Recent important trials of pharmacotherapy in Parkinson’s disease

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 1025-1028

Informa Healthcare

Access to resources Recommend Favorite

Implementing NICE clinical guidelines on Parkinson’s disease

By Ryton Beverly A   Liddle B Jane  

Clinical Medicine, Vol. 9, Iss. 5, 2009-10 ,pp. : 436-440

Royal College Of Physicians

Access to resources Recommend Favorite

Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?

By  

Current Medicinal Chemistry, Vol. 25, Iss. 31, 2018-09 ,pp. : 3682-3702

Bentham Science Publishers

Access to resources Recommend Favorite

Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes

By East S.J.   Hill M.P.   Brotchie J.M.  

European Journal of Pharmacology, Vol. 277, Iss. 1, 1995-04 ,pp. : 117-121

Elsevier

Access to resources Recommend Favorite